These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 30626244)

  • 1. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
    Jean SS; Gould IM; Lee WS; Hsueh PR;
    Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant
    Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
    Wright H; Bonomo RA; Paterson DL
    Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms.
    Koenig C; Kuti JL
    Pharmacotherapy; 2024 Aug; 44(8):658-674. PubMed ID: 38949413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.